INT130039

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.66
First Reported 2006
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 6
Disease Relevance 3.03
Pain Relevance 0.47

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (Dpp4) extracellular region (Dpp4) cell adhesion (Dpp4)
Golgi apparatus (Dpp4) endoplasmic reticulum (Dpp4) plasma membrane (Dpp4)
Anatomy Link Frequency
beta cell 1
saliva 1
Dpp4 (Mus musculus)
Pain Link Frequency Relevance Heat
agonist 74 96.28 Very High Very High Very High
tolerance 18 90.86 High High
Onset of action 2 86.56 High High
Paracetamol 4 74.52 Quite High
Pain 4 68.76 Quite High
Inflammation 10 5.00 Very Low Very Low Very Low
cytokine 6 5.00 Very Low Very Low Very Low
Neuropeptide 4 5.00 Very Low Very Low Very Low
ischemia 4 5.00 Very Low Very Low Very Low
abdominal pain 4 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Monsters 2 97.56 Very High Very High Very High
Diabetes Mellitus 405 97.12 Very High Very High Very High
Aging 5 95.76 Very High Very High Very High
Weight Loss 32 93.56 High High
Impaired Glucose Tolerance 16 90.86 High High
Obesity 36 76.00 Quite High
Nociception 1 75.00 Quite High
Hypoglycemia 119 70.56 Quite High
Pain 1 68.76 Quite High
Overactive Bladder 1 68.40 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
It exhibits a dipeptidyl-peptidase activity (DPP-IV) that cleaves the penultimate proline from the N-terminus of polypeptides, thereby regulating their activity and concentration.
Protein_catabolism (cleaves) of DPP-IV
1) Confidence 0.66 Published 2006 Journal Behav. Brain Res. Section Abstract Doc Link 16154213 Disease Relevance 0.07 Pain Relevance 0
Blocking the endogenous enzyme, DPP-4, which degrades active GLP-1, which is also effective in elevating to normal the reduced circulating GLP-1 levels that are present in T2DM.
Protein_catabolism (degrades) of DPP-4 associated with diabetes mellitus
2) Confidence 0.34 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941781 Disease Relevance 1.02 Pain Relevance 0.05
As individuals progress from normal glucose tolerance to IGT to T2DM, stimulated GLP-1 levels decline89,90 (Figure 7), and there is beta cell resistance to the glucose-dependent stimulatory effect of both GLP-1 and GIP on insulin secretion.91 In T2DM the contribution of incretin hormones to the insulin response has been estimated to be reduced to about 36% in T2DM subjects.86,92 From the therapeutic standpoint, one can increase circulating GLP-1 levels by administering a GLP-1 analog that is resistant to DPP-4 degradation or by giving a DPP-4 inhibitor.7,93,94
Protein_catabolism (degradation) of DPP-4 in beta cell associated with diabetes mellitus, tolerance and impaired glucose tolerance
3) Confidence 0.33 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941781 Disease Relevance 0.58 Pain Relevance 0.05
It was developed from exendin-4, found in the saliva of the gila monster lizard,55 has approximately 50% homology with human GLP-1, but binds more avidly to GLP-1 receptors, and is resistant to degradation by DPP-4, thus prolonging its duration of effect.56 Exenatide is administered twice daily in a dose of 5 or 10 ?
Protein_catabolism (degradation) of DPP-4 in saliva associated with monsters
4) Confidence 0.23 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2731024 Disease Relevance 0.24 Pain Relevance 0.14
Liraglutide has 97% homology with GLP-1, and is longer-acting than exenatide because of an attached free fatty acid derivative that increases non-covalent binding to albumin, and renders it more resistant to DPP-4 degradation, which slows renal clearance and absorption from the subcutaneous injection site.72 Its half-life is ?
Protein_catabolism (degradation) of DPP-4
5) Confidence 0.20 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2731024 Disease Relevance 0.18 Pain Relevance 0.16
The two main categories of incretin therapy currently available are: glucagon-like peptide-1 (GLP-1) analogues and inhibitors of GLP-1 degrading enzyme dipeptidyl peptidase-4 (DPP-4).
Protein_catabolism (degrading) of dipeptidyl peptidase-4
6) Confidence 0.07 Published 2008 Journal Drugs Aging Section Abstract Doc Link 18947259 Disease Relevance 0.94 Pain Relevance 0.07

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox